Results of a study examing the combination of dose adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab for first line treatment of Burkitt’s lymphoma.
Home / Resource Library / Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma